Manager TitleAgeSince
Corporate Secretary 60 2019-08-07
Director TitleAgeSince
Director/Board Member 49 2020-04-20
Director/Board Member 60 2019-06-06
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.16%-2.14%-21.86%-16.36% 23.28B
-0.94%-1.50%+3.06%+421.46% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.17%-0.68%+24.00%+179.24% 13.99B
Average -0.87%+0.47%+41.72%+175.20% 26.89B
Weighted average by Cap. -0.83%+1.47%+42.60%+138.15%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-